These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39250241)

  • 1. Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.
    Smith MR; Dixon CB; Wang Y; Liu Y; D'Agostino R; Ruiz J; Oliver G; Miller LD; Topaloglu U; Chan MD; Farris M; Su J; Mileham KF; Zhao D; Li W; Sexton T; Lycan T; Haas KM; Grayson JM; Xing F
    Cancer Res; 2024 Dec; 84(23):4002-4016. PubMed ID: 39250241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization.
    Cheng Y; Han X; Lai X; Wei X
    Phytomedicine; 2024 Dec; 135():156093. PubMed ID: 39531934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer.
    Wang Y; Ju X; Hua R; Chen J; Dai X; Liu L; Wang G; Bai Y; Hu H; Li X
    Br J Cancer; 2024 Dec; 131(11):1833-1845. PubMed ID: 39455880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer.
    Elkrief A; Montesion M; Sivakumar S; Hale C; Bowman AS; Begüm Bektaş A; Bradic M; Kang W; Chan E; Gogia P; Manova-Todorova K; Mata DA; Egger JV; Rizvi H; Socci ND; Kelly DW; Rosiek E; Meng F; Tam G; Fan N; Drilon A; Yu HA; Riely GJ; Rekhtman N; Quintanal Villalonga Á; Dogan S; Bhanot U; Gönen M; Loomis B; Hellmann MD; Schoenfeld AJ; Ladanyi M; Rudin CM; Vanderbilt CM
    J Clin Oncol; 2024 Oct; 42(28):3339-3349. PubMed ID: 39038258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
    Kato Y; Matsumoto M; Takano N; Hirao M; Matsuda K; Tozuka T; Onda N; Nakamichi S; Takeuchi S; Miyanaga A; Noro R; Gemma A; Seike M
    Cancer Med; 2024 Jun; 13(12):e7393. PubMed ID: 38923428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti-PD-1 in Murine Non-Small Cell Lung Cancer.
    Du Y; Salehi-Rad R; Zhang TH; Crosson WP; Abascal J; Chen D; Shi Y; Jiang H; Tseng YW; Ma X; Hong M; Wang S; Wang X; Tang K; Hu S; Li Y; Ni S; Cai Y; Tappuni S; Shen Y; Liu B; Sun R
    Cancer Immunol Res; 2024 Dec; 12(12):1765-1779. PubMed ID: 39325056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential predictive value of resident memory CD8
    Paolini L; Tran T; Corgnac S; Villemin JP; Wislez M; Arrondeau J; Johannes L; Ulmer J; Vieillard LV; Pineau J; Gey A; Quiniou V; Barennes P; Pham HP; Gruel N; Hasan M; Libri V; Mella S; De Percin S; Boudou-Rouquette P; Caidi A; Cremer I; Blons H; Leroy K; Laurent-Puig P; De Saint Basile H; Gibault L; Ravel P; Mami-Chouaib F; Goldwasser F; Fabre E; Damotte D; Tartour E
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39631852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhu Y; She J; Sun R; Yan X; Huang X; Wang P; Li B; Sun X; Wang C; Jiang K
    Front Immunol; 2024; 15():1493773. PubMed ID: 39575263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study.
    Masuda T; Tsubata Y; Hata K; Horie M; Kiura K; Kanaji N; Inoue T; Kodani M; Yanai M; Yamaguchi K; Matsumoto N; Yamasaki M; Ishikawa N; Masuda K; Takigawa N; Kuyama S; Kubota T; Nishii K; Hotta K; Hattori N
    Thorac Cancer; 2024 Dec; 15(34):2408-2417. PubMed ID: 39415454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Saalfeld FC; Möller J; Christopoulos P; Wenzel C; Rasokat A; Wang XA; Vathiotis I; König D; Illini O; Grohé C; Wiesweg M; Wesseler C; Schubart C; Pelusi N; Rohde G; Overbeck TR; Kirfel J; Alt J; Kauffmann-Guerrero D; Griesinger F; Kulhavy J; Allgäuer M; Klimova A; Schütz M; Aust DE; Hochmair MJ; Rothschild SI; Syrigos KN; Veluswamy R; Michels S; Stenzinger A; Jöhrens K; Wermke M
    Eur J Cancer; 2024 Dec; 213():115065. PubMed ID: 39423775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence Risk and Its Impact on Current Treatment Strategies in Early and Locally Advanced NSCLC.
    Tegenbosch C; Vekens K
    Anticancer Res; 2024 Dec; 44(12):5495-5500. PubMed ID: 39626904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study.
    Gao Z; Teng J; Qiao R; Qian J; Pan F; Ma M; Lu J; Zhang B; Chu T; Zhong H
    JMIR Res Protoc; 2024 Nov; 13():e64950. PubMed ID: 39514267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC.
    Li H; Liu J; Zhang L; Xu Y; Wang X; Lan S; Cui P; Wang G; Cai S; Cheng Y
    J Immunother Cancer; 2024 Nov; 12(11):. PubMed ID: 39615893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell analysis reveals the disparities in immune profiles between younger and elder patients.
    Dong H; Hu F; Hao B; Jin X; Zheng Q; Su Y
    Eur Geriatr Med; 2024 Oct; 15(5):1509-1522. PubMed ID: 39244673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China.
    Li H; Yuan Y; Xu Q; Liang G; Hu Z; Li X; Zhang W; Lei H
    Front Immunol; 2024; 15():1487078. PubMed ID: 39635526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B
    Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations.
    Wang Y; Wei J; Xu M; Xiang J; Shao K; Hao Y; Song Z
    Clin Transl Oncol; 2024 Oct; 26(10):2503-2512. PubMed ID: 38627317
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.